Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 15/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781511 | 0.92 | FGFR1 (0.59) | FGFR1ATMKDRHTTALDH1A1 | |
| SCHEMBL19781594 | 0.87 | ATM (0.58) | FGFR1ATMKDRHTTALDH1A1 | |
| SCHEMBL19781574 | 0.82 | FGFR1 (0.49) | FGFR1ATMKDRHTTALDH1A1 | |
| SCHEMBL19781512 | 0.82 | FGFR1 (0.52) | FGFR1ATMKDRHTTALDH1A1 | |
| SCHEMBL21449931 | 0.81 | ATM (0.53) | FGFR1ATMKDRHTTALDH1A1 | |
| SCHEMBL21436088 | 0.80 | FGFR1 (0.43) | FGFR1ATMHTTALDH1A1HPGD | |
| SCHEMBL19781509 | 0.78 | GABRP (0.52) | FGFR1ATMKDRHTTALDH1A1 | |
| SCHEMBL19781251 | 0.78 | FGFR1 (0.58) | FGFR1KDRHTTALDH1A1HPGD | |
| SCHEMBL19781510 | 0.77 | GABRP (0.56) | FGFR1ATMKDRHTTALDH1A1 | |
| SCHEMBL19781279 | 0.77 | KDR (0.68) | FGFR1ATMKDRHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | FGFR1 3928/4885ATM 4747/4885KDR 3283/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | FGFR1 3928/4885ATM 4747/4885KDR 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.